Wellington Management Group LLP Buys 520,898 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Wellington Management Group LLP increased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 3,592.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 535,396 shares of the company's stock after purchasing an additional 520,898 shares during the quarter. Wellington Management Group LLP owned 0.91% of Janux Therapeutics worth $28,665,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Lester Murray Antman dba SimplyRich increased its holdings in shares of Janux Therapeutics by 205.3% in the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after buying an additional 16,351 shares during the period. abrdn plc purchased a new stake in Janux Therapeutics during the 4th quarter valued at about $3,430,000. Barclays PLC grew its position in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after acquiring an additional 144,883 shares during the last quarter. Legal & General Group Plc increased its stake in Janux Therapeutics by 45.3% in the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock worth $1,849,000 after purchasing an additional 10,776 shares during the period. Finally, Rhumbline Advisers lifted its position in Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after purchasing an additional 599 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the acquisition, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67% increase in their position. The disclosure for this purchase can be found here. Company insiders own 8.10% of the company's stock.

Janux Therapeutics Trading Up 5.1%

NASDAQ JANX traded up $1.21 during trading on Monday, hitting $25.01. The company had a trading volume of 853,655 shares, compared to its average volume of 884,360. The company's fifty day moving average is $27.37 and its 200-day moving average is $38.49. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -21.38 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on JANX. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reissued an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.